Abstract
Androgen deprivation therapy (ADT) alone or in combination with radiation therapy or other drugs is increasingly used for the treatment of localized, high-risk, or biochemical relapse of prostate cancer (PC). Bone mineral density (BMD) loss is rapid during the first year of ADT; up to 4.6% of total hip, femoral neck, and lumbar spine BMD loss has been reported in PC patients without bone metastases (nonmetastatic PC). In prospective studies, concurrent administration of a bisphosphonate or selective estrogen receptor modulator stabilized or increased BMD. Results of retrospective studies of ADT-treated patients who did not receive antiresorptive therapy have demonstrated a 21–37% increase in fracture risk. Because of the documented bone loss and increased fracture risk, patients should receive adequate counseling, monitoring, and therapy aimed at preventing or treating ADT-induced bone loss. Future studies should address the long-term impact of antiresorptive therapy on actual fracture rate and the impact on quality of life and healthcare costs.
Key Points
-
Prospective data show that ADT significantly increases the risk of BMD loss in men with nonmetastatic prostate cancer
-
Men initiating ADT should have an assessment of risk factors, calcium and vitamin D intake, lifestyle modification counseling, and baseline and follow-up BMD assessments
-
Men with established osteoporosis are candidates for treatment with a bisphosphonate; a SERM would be a reasonable alternative for those men with contraindications to bisphosphonate therapy
-
Bisphosphonate or SERM therapy to prevent further bone loss should be considered for men with osteopenia and/or other high-risk factors for bone loss
-
Prospective trials on fracture risk due to ADT have not been completed, however, low BMD is a robust predictor of fracture risk in other populations, and data from these populations should be used to inform treatment strategies until prostate cancer-specific data is available
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal A et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43–66
Higano CS (2004) Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin N Am 31: 331–352
The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (version 2.2007). © 2006 National Comprehensive Cancer Network, Inc. [http://www.nccn.org] (accessed 15 May 2007)
Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–108
Pilepich MV et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285–1290
D'Amico AV et al. (2004) 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827
Messing EM et al. (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7: 472–479
Pettersson B et al. (2006) Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate: 12-month follow-up study. Eur Urol 50: 483–489
Jenkins VA et al. (2005) Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96: 48–53
Herr HW et al. (2000) Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163: 1743–1746
Shahinian VB et al. (2006) Risk of “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166: 465–471
Schow DA et al. (1998) Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 91: 855–857
Potosky AL et al. (2002) Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94: 430–437
Choo R et al. (2005) How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients. Can J Urol 12: 2547–2552
Bogdanos J et al. (2003) Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res 23: 1757–1762
Smith MR et al. (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91: 1305–1308
Maillefert JF et al. (1999) Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161: 1219–1222
Mittan D et al. (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87: 3656–3661
Ryan CW et al. (2006) Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176: 972–978
Michaelson MD et al. (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist–induced bone loss in men with prostate cancer. J Clin Oncol 25: 1038–1042
Smith MR et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948–955
Berruti A et al. (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167: 2361–2367
Israeli RS et al. (2007) The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 5: 271–277
Smith MR et al. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008–2012
Greenspan SL et al. (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90: 6410–6417
Greenspan SL et al. (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146: 416–424
Higano C (2006) Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin N Am 20: 909–923
Weston R et al. (2005) Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone–releasing hormone analogue therapy in osteoporotic patients with prostate cancer. BJU Int 95: 776–779
Kaku H et al. (2005) Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66: 439–444
Nejat RJ et al. (2000) A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164: 1891–1894
Gulley JL et al. (2005) A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173: 1567–1571
Riggs BL et al. (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23: 279–302
Eastell R et al. (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res 21: 1215–1223
Fogelman I et al. (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14: 1001–1006
Higano C et al. (2004) Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64: 1182–1186
Smith MR et al. (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23: 7897–7903
Shahinian VB et al. (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 154–164
Smith MR et al. (2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175: 136–139
Schuit SCE et al. (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34: 195–202
Adachi JD et al. (2001) The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 12: 903–908
Center JR et al. (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353: 878–882
Kaufman JM et al. (2000) Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 59: 765–772
Chien AJ et al. (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24: 5305–5312
Morote J et al. (2003) Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 44: 661–665
Morote J et al. (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69: 500–504
Ryan CW et al. (2007) Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70: 122–126
Kiratli J et al. (2001) Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57: 127–132
Blake GM et al. (1998) Applications of bone densitometry for osteoporosis. Endocrinol Metab Clin North Am 27: 267–288
Agarwal MM et al. (2005) Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103: 2042–2052
Conde FA et al. (2004) Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 64: 335–340
Finkelstein JS (2000) Osteoporosis. In Cecil Textbook of Medicine, 1366–1373 (Eds Goldman L et al.) Philadelphia: WB Saunders Company
Smith MR et al. (2001) Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 91: 2238–2245
Planas J et al. (2007) The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int 99: 812–816
Kanis JA et al. (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12: 989–995
Faulkner KG (2000) Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 15: 183–187
Cummings SR et al. (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 21: 1550–1556
Siris ES et al. (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA 286: 2815–2822
Selby PL et al. (2000) Do men and women fracture bones at similar bone densities? Osteoporos Int 11: 153–157
Orsini LS et al. (2005) Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 16: 359–371
Segal RJ et al. (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21: 1653–1659
Sawka AM et al. (2005) Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 16: 1836–1840
Burge R et al. (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22: 465–475
Kiebzak GM et al. (2002) Undertreatment of osteoporosis in men with hip fractures. Arch Intern Med 162: 2217–2222
Gregg EW et al. (1998) Physical activity and osteoporotic fractures risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 129: 81–88
Ettinger B et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645
Ringe JD et al. (2004) Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24: 110–113
Black DM et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822
Dawson-Hughes B et al. (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 337: 670–676
Smith MR et al. (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89: 3841–3846
Michaud LB et al. (2006) Cancer-treatment-induced bone loss, part 2. Am J Health-Syst Pharm 63: 534–546
Diamond TH et al. (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100: 892–899
Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359: 2018–2026
Reid IR et al. (1995) Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 98: 331–335
Peacock M et al. (2000) Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 85: 3011–3019
Eriksson S et al (1999) Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57: 97–99
Fosamax® package insert (Merck & Co, Inc. 2006)
Actonel® package insert (sanofi-aventis 2007)
Boniva® package insert (Roche Laboratories, Inc. 2006)
ClinicalTrials.gov [http://www.clinicaltrials.gov/ct/show/NCT00329797?order=1] (accessed 15 May 07)
Scherr D et al. (2002) Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 167: 535–538
Taxel P et al. (2002) The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 7: 4907–4913
Smith PD (2005) Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol 2: 608–615
Hillner BE et al. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042–4057
Delmas PD (2000) Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11 (Suppl 6): S66–S76
Medicare Coverage Database. Centers for Medicare & Medicaid Services [http://www.cms.hhs.gov/mcd/viewlcd.asp?lcd_id=23694&lcd_version=4& show=all] (accessed 15 May 2007)
Acknowledgements
The author thanks Stephanie Butler, Lisa Holle, and Laura Jung, who assisted with manuscript development and provided editorial services. This work was supported in part by Novartis Oncology. Désirée Lie, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Higano, C. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?. Nat Rev Urol 5, 24–34 (2008). https://doi.org/10.1038/ncpuro0995
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0995
This article is cited by
-
Validation of JSBMR’s CTIBL manual for Japanese men receiving androgen deprivation therapy for prostate cancer
Journal of Bone and Mineral Metabolism (2023)
-
The effects of exercise on the bone health of people with cancer: a systematic review and meta-analysis
Osteoporosis International (2022)
-
Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea
Scientific Reports (2021)
-
Reduction in femoral neck and total hip bone mineral density following hospitalisation for diabetes-related foot ulceration
Scientific Reports (2021)
-
Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study
Scientific Reports (2017)